Angina Pectoris Drugs Market by Type, Drugs, Route of Administration, Distribution Channel, End-Users

KEY MARKET STATISTICS
Base Year [2023]	USD 1.14 billion
Estimated Year [2024]	USD 1.20 billion
Forecast Year [2030]	USD 1.65 billion
CAGR (%)	5.39%

The FPNV Positioning Matrix is pivotal in evaluating the Angina Pectoris Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angina Pectoris Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Prinzmetal Angina
- Stable Angina
- Unstable Angina
Drugs
- Anti-Ischemic Agents
- Antihypertensive Agents
- Antiplatelet Agents
- Beta-Adrenergic Blocking Agents
- Calcium Channel Blockers
- Nitrates
- Statins
Route of Administration
- Oral
- Parenteral
- Transdermal
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
End-Users
- Homecare
- Hospitals
- Specialty Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Angina Pectoris Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angina Pectoris Drugs Market?

3. What are the technology trends and regulatory frameworks in the Angina Pectoris Drugs Market?

4. What is the market share of the leading vendors in the Angina Pectoris Drugs Market?

5. Which modes and strategic moves are suitable for entering the Angina Pectoris Drugs Market?

Product Code: MRR-742BD517AD28

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Angina Pectoris Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
  - 5.1.1.2. Augmentation of novel drug delivery systems
  - 5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
- 5.1.2. Restraints
  - 5.1.2.1. Concerns regarding side effects associated with certain drug classes
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements towards personalized cardiovascular medicine
  - 5.1.3.2. Proliferation in the number of drug approvals and clinical research
- 5.1.4. Challenges
  - 5.1.4.1. Dearth of skilled and experienced professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Angina Pectoris Drugs Market, by Type

6.1. Introduction
6.2. Prinzmetal Angina
6.3. Stable Angina
6.4. Unstable Angina

7. Angina Pectoris Drugs Market, by Drugs

7.1. Introduction
7.2. Anti-Ischemic Agents
7.3. Antihypertensive Agents
7.4. Antiplatelet Agents
7.5. Beta-Adrenergic Blocking Agents
7.6. Calcium Channel Blockers
7.7. Nitrates
7.8. Statins

8. Angina Pectoris Drugs Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Transdermal

9. Angina Pectoris Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy

10. Angina Pectoris Drugs Market, by End-Users

10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics

11. Americas Angina Pectoris Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Angina Pectoris Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Angina Pectoris Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Alembic Pharmaceuticals Limited
- 15.1.2. Alkem Laboratories Ltd.
- 15.1.3. Astellas Pharma Inc.
- 15.1.4. AstraZeneca PLC
- 15.1.5. Bausch Health Companies Inc.
- 15.1.6. Bayer AG
- 15.1.7. Centurion Remedies Private Limited
- 15.1.8. Dr. Reddy's Laboratories
- 15.1.9. Eli Lilly and Company
- 15.1.10. Gilead Sciences, Inc.
- 15.1.11. GlaxoSmithKline PLC
- 15.1.12. Intas Pharmaceuticals Ltd.
- 15.1.13. Ipca Laboratories Ltd.
- 15.1.14. Lupin Ltd.
- 15.1.15. Macleods Pharmaceuticals Pvt Ltd.
- 15.1.16. Mankind Pharma
- 15.1.17. Merck & Co. Inc.
- 15.1.18. Novartis AG
- 15.1.19. Otsuka Pharmaceutical Co., Ltd.
- 15.1.20. Pfizer Inc.
- 15.1.21. Sanofi-Aventis Groupe S.A.
- 15.1.22. Sumitomo Corporation
- 15.1.23. Sun Pharmaceutical Industries Ltd.
- 15.1.24. Teva Pharmaceutical Industries Ltd.
- 15.1.25. Torrent Pharmaceuticals Ltd.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing